A 23-year-old white male was admitted to the hospital because of previously diagnosed schizophrenia and increasing suicidal ideation. For six months prior to admission he had been receiving haloperidol, 15 mg daily, and benztropine mesylate, 6 mg daily. Three months prior to admission, because of increasing depression, imipramine, 150 mg daily was added to his therapeutic regimen.
At the time of admission there was no history of drug abuse or alcohol ingestion. His medical history was entirely negative and his physical examination was entirely normal. All medications were discontinued in order to clarify the patient's diagnosis. Initial laboratory work, including liver function studies (SGOT, SGPT, LDH, alkaline phosphatase, total bilirubin), blood urea nitrogen, serum electrolytes, electroencephalogram and chest and skull X-rays, was entirely within normal limits.
On the third hospital day, the patient complained of nausea, anorexia and vomiting. Physical examination was again negative and revealed no abdominal tenderness or distension, and no evidence of increased intracranial pressure. It was felt that the symptoms represented a reaction to the withdrawal of neuroleptic medication and no treatment was given.
The vomiting did not subside as ex- pected, and six days later it was noted that the patient had lost eleven pounds since admission. Repeat blood tests at this time revealed a blood urea nitrogen of 44 mg %, chlorides of 79 meq.z1., CO 2 content of 37 mM., potassium of 2.7 meq,fl., and sodium of 144 meq.Zl , A diagnosis of dehydration and metabolic alkalosis secondary to persistent vomiting was made. For four days the patient received no fluids by mouth and his metabolic disturbances were corrected with intravenous fluid therapy. Vomiting continued and a gastroenterology consultation was obtained. Physical examination throughout his course continued to be negative and liver function studies, serium lipase, serum amylase, glucose and calcium determinations were also normal. An upper gastrointestinal X-ray series and gastroscopy with visualization to the third portion of the duodenum were normal. After the tenth day of protracted vomiting, treatment with antacids was started. When the patient was able to retain sufficient fluid by mouth, intravenous fluids were discontinued, although the vomiting persisted (four to eight times daily). Observation of the patient's behaviour, psychiatric testing and clinical examination confirmed the diagnosis of schizophrenia and treatment with haloperidol, 15 mg daily, and benztropine mesylate, 6 mg daily, was reinstituted. Over the following week there was a steady diminution in the severity of nausea and frequency of vomiting, and nineteen days after the onset of symptoms, three weeks following discontinuation of medication, the patient's vomiting ceased.
He was able to resume normal hospital activities and was discharged two weeks later on these medications without further vomiting.
Discussion
This case is reported to illustrate the severity of vomiting which can follow abrupt discontinuation of neuroleptic, antidepressant, and antiparkinsonian medications. We would postulate that this patient's withdrawal reaction might be explained by the simultaneous and additive effects of two distinct physiologic mechanisms.
Sudden cessation of imipramine therapy is known to cause a withdrawal syndrome including nausea and vomiting as cardinal features (3, 5) . In our experience, however, such reactions have not lasted so long as seen in this patient, nor has the vomiting led to such severe fluid and electrolyte disturbances.
Symptoms following sudden withdrawal of butyrophenones have also been described. These include primarily extrapyramidal syndromes, dyskinesias and akathesias (2) as well as a general withdrawal picture, which may include nausea and vomiting (4). We are not aware of any other cases of haloperidol withdrawal with vomiting of the severity experienced by our patient.
Vomiting, together with paralytic ileus and abdominal pain, has been reported as a side effect of treatment with benztropine mesylate (7) . However, we have been unable to find any reports of protracted vomiting following sudden cessation of this drug.
From the extensive investigation of this patient, we have concluded that his vomiting and subsequent metabolic alkalosis were probably caused by the sudden discontinuation of medication. The removal of the parasympathetic blocking effects of imipramine and benz tropine mesylate might be seen as a likely cause of his symptomatology. Both these medications share marked anticholinergic properties, and a cholinergic rebound phenomenon may occur in any patient receiving medications with these properties. Such a rebound effect was suggested by Simpson et al. (6) in studies of withdrawal reactions following the use of phenothiazines combined with anti parkinson ian agents. This work has been supported by that of Sun et al. on gastric acid production and inhibition (8) .
In addition to the cholinergic rebound mechanism, another explanation for the patient's vomiting is that postulated by Yepes and Winsberg in their recent report of vomiting in children following neuroleptic withdrawal (9) . The removal of haloperidol's marked dopamine-blocking properties may have led to the hypersensitivity of the dopamine receptors of the medullary chemoreceptor trigger zone, resulting in severe vomiting (1) .
The interaction of these two distinct withdrawal mechanisms might explain the unusual severity of this patient's vomiting. While the action of either process by itself might not have produced the clinical picture which we encountered, their additive and possibly synergistic effects may account for the severity of this patient's withdrawal syndrome. Clinicians should thus be aware not only of the withdrawal effects of medication, but the likely mechanisms producing such reactions, since different drugs cause similar symptoms via different mechanisms. In addition, this case recalls the need to proceed cautiously when changing or stopping neuroleptic medica-. tion, and supports the importance of avoiding abrupt discontinuation whenever possible.
Summary
The case of a 23-year-old patient treated with haloperidol, imipramine, and benztropine mesylate is presented to illustrate an unusually severe reaction to the abrupt cessation of neuroleptic medication.
In addition to the description of the withdrawal reaction, a possible explanation of the clinical phenomenon is offered. 
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